{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:10:07Z","timestamp":1760782207070,"version":"3.41.2"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1997,9,1]],"date-time":"1997-09-01T00:00:00Z","timestamp":873072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1997,9,1]],"date-time":"1997-09-01T00:00:00Z","timestamp":873072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1997,9]]},"DOI":"10.1023\/a:1005854510468","type":"journal-article","created":{"date-parts":[[2002,12,21]],"date-time":"2002-12-21T18:56:21Z","timestamp":1040496981000},"page":"235-246","source":"Crossref","is-referenced-by-count":10,"title":["A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors"],"prefix":"10.1007","volume":"15","author":[{"given":"Nancy T.","family":"Sklarin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan D.","family":"Lathia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Williamn R.","family":"Grove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi I.","family":"Einzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter H.","family":"Wiernik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"142511_CR1","first-page":"791","volume":"42","author":"GP Wheeler","year":"1982","unstructured":"Wheeler GP, Bowden BJ, Werline JA, Adamson DJ, Temple CG: Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,3-dihydro-3[(N-,methylanilino)-methyl]-pyrido-[3,4]pyrazine-7-ylcarbamate (NSC 181928). Cancer Res 42: 791\u2013799, 1982.","journal-title":"Cancer Res"},{"key":"142511_CR2","first-page":"1621","volume":"47","author":"BJ Bowden","year":"1987","unstructured":"Bowden BJ, Waud WR, Wheeler GP, Hain RH, Dansby L, Temple CG: Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis. Cancer Res 47: 1621\u20131626, 1987.","journal-title":"Cancer Res"},{"key":"142511_CR3","first-page":"3239","volume":"50","author":"WR Waud","year":"1990","unstructured":"Waud WR, Leopold WR, Elliot WL, Dykes DJ, Laster WR, Temple CG, Harrison SD, Griswold DP: Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido[3,4-b]pyrazin-7-ylcarbamate,2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res 50: 3239\u20133244, 1990.","journal-title":"Cancer Res"},{"key":"142511_CR4","first-page":"A485","volume":"5","author":"SN Kim","year":"1991","unstructured":"Kim SN, Watkins JR, Gough AW: Intravenous toxicity of CI-980, a mitotic inhibitor in mice and rats. FASEB J 5: A485, 1991.","journal-title":"FASEB J"},{"key":"142511_CR5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/019262339101900214","volume":"19","author":"CL Courtney","year":"1991","unstructured":"Courtney CL, Kim SN, Walsh KM, Watkins JR, Dominick MA: Proliferative bone lesions in rats given anticancer compounds. Toxicol Pathol 19: 184\u2013188, 1991.","journal-title":"Toxicol Pathol"},{"key":"142511_CR6","first-page":"3163","volume":"33","author":"J Brodfuehrer","year":"1992","unstructured":"Brodfuehrer J, Whitfield LR, Kowal C, Grove MR, Bullen W, Waterhouse D, Natale R: Pharmacologically guided dose escalation in Phase I clinical trial of CI-980. Proc Am Assoc Cancer Res 33: 3163, 1992.","journal-title":"Proc Am Assoc Cancer Res"},{"key":"142511_CR7","first-page":"292","volume":"11","author":"R Natale","year":"1992","unstructured":"Natale R, Waterhouse D, Grove WR, Whitfield LR, Brodfuehrer J, Kowal C: Phase I clinical and pharmacokinetic trial of CI-980, a novel mitotic inhibitor. Proc Am Soc Clin Oncol 11: 292, 1992.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"142511_CR8","first-page":"1477","volume":"14","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky EK, Noe DA, Grochow LB, Bowling MK, Sartorious SE, O'Reilly S, Chen T-L, Donehower RC: Phase I and pharmacological study of CI-980, a synthetic and structurally unique antimicrotubule agent, on a 72-hour continuous influsion schedule in adults with solid tumors. Proc Am Soc Clin Oncol 14: 1477, 1995.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"142511_CR9","first-page":"1129","volume":"37","author":"J Gutheil","year":"1996","unstructured":"Gutheil J, Van Echo D, Egorin M, Panitch H, Swallow L, O'Hare S, Kearns C: Phase I study of CI-980 in patients with refractory malignancies. Proc Am Assoc Cancer Res 37: 1129, 1996.","journal-title":"Proc Am Assoc Cancer Res"},{"key":"142511_CR10","first-page":"479","volume":"14","author":"NT Sklarin","year":"1995","unstructured":"Sklarin NT, Benson L, Roca J, Einzig AI, Wiernik PH, Whitefield LR, Lathia CD, Kowal CD, Grove WR: Phase I study of CI-980: 24-hr infusion. Proc Am Soc Clin Oncol 14: 479, 1995.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"142511_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0378-4347(95)00067-S","volume":"668","author":"WW Bullen","year":"1995","unstructured":"Bullen WW, Whitfield LR, Walter GA, Brodfeuhrer JI: High-performance liquid chromatographic assay for CI-980, a novel 1-deaza-7,8-dihydropteridine anticancer agent, in human plasma and urine. J Chromatog Biomed Appl 668: 141\u2013151, 1995.","journal-title":"J Chromatog Biomed Appl"},{"key":"142511_CR12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0010-468X(83)90082-X","volume":"16","author":"ML Rocci","year":"1983","unstructured":"Rocci ML, Jusko WJ: LAGRAN program for area and moments in pharmacokinetic analysis. Comput method programs biomed 16: 203, 1983.","journal-title":"Comput method programs biomed"},{"issue":"10","key":"142511_CR13","first-page":"259","volume":"8","author":"JI Brodfeuhrer","year":"1991","unstructured":"Brodfeuhrer JI, Wong BK, Bullen WW, Andress LD, Whitfield LR: Disposition of CI-980, a novel mitotic inhibitor, in mouse and dog. Pharm Res 8(10): 259, 1991.","journal-title":"Pharm Res"},{"key":"142511_CR14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T: Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093\u20131095, 1993.","journal-title":"Pharm Res"},{"key":"142511_CR15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF03259853","volume":"1","author":"SS Legha","year":"1986","unstructured":"Legha SS: Vincristine neurotoxicity: pathophysiology and management. Med Toxicol 1: 421, 1986.","journal-title":"Med Toxicol"},{"issue":"suppl3","key":"142511_CR16","first-page":"1","volume":"20","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC: Clinical toxicities encountered with paclitaxel (Taxol). Sem Oncol 20(suppl 3): 1, 1993.","journal-title":"Sem Oncol"},{"key":"142511_CR17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/mpo.2950160313","volume":"16","author":"RL Hurwitz","year":"1988","unstructured":"Hurwitz RL, Mahoney DH, Jr, Armstrong DL, et al: Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 16: 216, 1988.","journal-title":"Med Pediatr Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005854510468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1005854510468\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005854510468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:43:27Z","timestamp":1753818207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1005854510468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,9]]}},"alternative-id":["142511"],"URL":"https:\/\/doi.org\/10.1023\/a:1005854510468","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[1997,9]]}}}